ClinicalTrials.gg
RecruitingNCT07192965ECLECTICUpdated Sep 25, 2025

ECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain

An interventional study of Non-ECG-gated computed tomography in Chest Pain and Acute Coronary Syndromes (ACS), sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Study summary

Chest pain represents a common reason for consultation to emergency room. This symptom can be explained by a broad spectrum of conditions, from benign musculoskeletal or esophageal pain to life-threatening disease such as aortic dissection, pulmonary embolism, and myocardial infarction.

There are already different diagnostic tools to quickly identify most dangerous diseases, for example electrocardiogram, blood samples with specific markers of cardiac injury, chest X-ray and echography. In case a doubt of disease is raised after the first clinical evaluation, it is possible to proceed with more complex, expensive and invasive examinations, namely a computed tomography (CT) scan or an invasive coronary angiography (ICA).

CT scan allows the diagnosis of various conditions such as pleural, pulmonary, pericardial and vascular disease such as pneumonia, pneumothorax, pleural and pericardial fluid, pulmonary embolism (PE), acute aortic dissection (AOD). In order to see the pulmonary, aortic and coronary arteries, a contrast injection is needed. Moreover, since the heart and the aortic root are continuously moving, specific technical measures to obtain good quality images are needed.

Recently, a new CT scan system has been developed. It allows to obtain good quality images of the heart and aortic root using an estimated heart rhythm, without ECG-gating. This allows to perform a CT scan of the heart in a reduced amount of time, and without need for controlling heart rate. Moreover, it is possible to obtain information on both aortic, coronary, and pulmonary artery with the same contrast injection. This may be of great interest in the context of patients presenting at the emergency room with chest pain and with a suspicion of pulmonary embolism, myocardial infarction, or aortic dissection, since with a single fast exam it is possible to rule out all these conditions.

Coronary arteries are very small vessels, and the accuracy of this new technique in identifying a significant obstruction is still to be proved. At present, patients with chest pain and a suspicion of myocardial infarction undergo an invasive coronary angiography. If this new tool proves to be reliable, it will be possible to reduce the number of useless invasive examination in patients in which the presence of coronary artery disease (CAD) is ruled-out. In addition, the CT scan can help quickly and effectively plan treatment when worrying abnormalities are detected in the coronary arteries that are associated with a higher risk.

Therefore, this clinical trial (further on referred to as "trial") will evaluate the investigational medicinal product (IMP), ECG-less Revolution Apex Elite system (GE Healthcare, Waukesha, WI -USA) for the diagnosis of coronary artery disease. The purpose of this trial is to learn about: the accuracy of this new CT system compared to the gold standard invasive coronary angiography in diagnosing coronary artery disease. The number of patients receiving an alternative diagnosis such as pulmonary embolism, aortic dissection, pulmonary, pleural or pericardial disease will be evaluated. Finally, the prognostic predictive value of the CT compared with ICA, in predicting myocardial infarction, coronary revascularization, and cardiac death at a follow-up of 18 months will be assessed. Patient will undergo a computer tomography examination with this new technique, evaluating both pulmonary, aortic, and coronary arteries. Then, as indicated by current guidelines, they will undergo an invasive coronary angiography.

Read the detailed description
  1. Study Rationale The aim is to investigate the potential role of CCTA in patients presenting to the emergency room with thoracic pain and elevated troponins. Using a single contrast bolus and a lower radiation dose, the new ECG-less CCTA could help exclude life-threatening conditions such as PE and AAD, while providing valuable information about the coronary arteries. Patients with normal coronary arteries could be safely discharged without invasive examinations, thus avoiding pro-cedural risks and optimizing both time and resources for medical institutions. However, since the diagnostic role of ECG-less CCTA in ACS has not yet been demonstrated, current guidelines and best practices will be followed in the management of enrolled patients. Decisions regard-ing PCI will be based on coronary angiography, coronary physiology, and intravascular imaging, as currently recommended by international guidelines.

    The negative and positive predictive value of the ECG-less CCTA compared to the standard of care (ICA) in patients clinically considered at risk for NSTEMI will be assessed. Additionally, the prognostic predictive value of CCTA in this clinical context, in compari-son to ICA will be evaluated. If the prognostic value of CCTA is similar to that of ICA, it will be possible to reduce the use of invasive procedures in favor of non-invasive exams, thereby saving time, contrast, and radia-tion dose for the patient.

  2. Primary Objectives

    • Evaluate the diagnostic accuracy of the non-ECG-gated CCTA in diagnosing CAD compared to the gold standard (ICA) in terms of negative and positive predictive value, sensitivity, and specificity.
    • Assess the accuracy in excluding high-risk CAD such as LM, proximal LAD and multivessel disease.
    • Describe the proportion of patients diagnosed as NSTE-ACS according to the ESC guidelines who will receive an alternative diagnosis thanks to the CCTA, in particular PE and AAD.
  3. Secondary Objectives

    • Assess the capacity of the non-ECG-gated CCTA in predicting the mid and long-term out-come compared to the ICA.
    • Investigate the possibility of applying the tool of FFR-CT calculation at images obtained by means of non-ECG-gated CCTA.
  4. Study Design Prospective, single-center, double-blinded study.
  5. Study Population Patients presenting at the ER with acute chest pain and either a diagnosis of NSTEMI at "high-risk" according to the 2023 ESC guidelines on ACS or a troponin value in the "observe pathway" and a high clinical suspicion of MI.
  6. Study protocol Patients presenting with acute chest pain and elevated troponin either in the "rule-in" or "ob-serve pathway" according to ESC guidelines on ACS will be offered to participate to this study evaluating the role of non-ECG-gated CTA in patients with NSTEMI. After giving the consent, patients will be sent for non-ECG-gated CTA for the evaluation of coronary arteries, ascendent aorta and pulmonary arteries. After the CT and within 24 hours, patients will undergo ICA. Both the patient and the interventional cardiologist will be blinded to the result of the CT, the only exception being the diagnosis of a disease other than CAD which is considered responsible for the clinical presentation. The analysis of the CT images will be repeated in a core lab by the consensus of two radiologist with a wide experience in CCTA. Readers will be blinded to clini-cal data and ICA results.

ECG-less CT Patients will undergo scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, which is always available since emergency patients are already monitored with finger pulse oximeter. Based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Acquisition can be performed over one full heart cycle, three-quarters, or half cycle, depending on heart rate. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used to enhance image quality and correct for motion. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus. No additional contrast will be administered for cardiac imaging. No intravenous β-blocker or sublingual nitroglycerin will be administered. The total added exam time (including heart rhythm assessment, scan preparation, delay, and the acquisition itself) is estimated at 1-2 minutes.

Invasive coronary angiography and revascularization Patients will undergo an ICA following local and international best practices. The UZ Brussel in-terventional department is a high-volume center with experience in complex percutaneous coronary interventions (PCI). The procedures will be performed with trans-radial access when feasible. Any attention will be paid to reduce the total amount of contrast.

In case of moderate stenosis, the operator will use the invasive FFR to indicate PCI. The use of intravascular imaging is encouraged.

In case of significant CAD, patients will be treated with PCI following the ESC guidelines. The choice of interventional technique and DAPT regimen is left to the operator and the treating cardiologist.

Complete revascularization will be pursued either during the same hospitalization or within one month.

02

Conditions studied

  • Chest Pain
  • Acute Coronary Syndromes (ACS)

Keywords

  • Chest pain
  • Acute coronary syndrome
  • NSTEMI
  • ECG-less coronary computed tomography angiography
  • ECG-les CCTA
03

In context

Chest Pain

389 studies on the registry are indexed under Chest Pain; 65 are open to participants now.

This study's planned enrollment of 230 is above the median of 128 across 205 interventional studies indexed under Chest Pain.

Browse Chest Pain studies →

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 30 years old
  • Admission at the ER with acute chest pain and at least one of the follow-ing:

    1. abnormality;
    2. positive rule-in criteria according to the ESC guidelines (hs-cTnT ≥ 52 in at least one assay or 1h ∆ ≥ 5);
    3. troponine value in the "observe pathway" (hs-cTnT ≥ 12 in at least one assay or 1h ∆ ≥ 3) AND a high clinical suspicion of MI.

Exclusion criteria

Exclusion Criteria:

  • Indication for urgent ICA (ST-elevation, hemodynamic or electric instabil-ity, chest pain, mechanical complications)
  • \< 30 ml/min
  • Previous coronary stenting
  • Previous CABG
  • Recent ACS within 6 months
  • Known severely reduced (EF \< 30%)
  • Contrast allergy
  • Inability to provide
  • Limited \< 2 years due to non-cardiac conditions
  • Pregnant and breast-feeding women
  • Known congenital heart disease
  • Atrial fibrillation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Other
    Single arm

    All patients will be before scanned with a ECG-less CCTA and then undergo invasive coronary angiography. There is one single arm.

    Radiation: Non-ECG-gated computed tomography

Interventions

  • RadiationNon-ECG-gated computed tomography

    Scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of ECG-less CCTA for detecting obstructive coronary artery disease (defined as luminal narrowing ≥ 50%), compared to invasive coronary angiography

    In both studies, sensitivity, specificity, positive and negative predictive value will be calculated. Diagnostic accuracy will be assessed using the McNemar test to compare CCTA with ICA. Cohen's Kappa agreement test will be used to evaluate agreement in diagnostic categorization between the two modalities.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Accuracy of CCTA in detecting high-risk CAD such as LM, proximal LAD and multivessel disease compared to invasive coronary angigoraphy

    Accuracy of CCTA in detecting high-risk CAD such as LM, proximal LAD and multivessel disease compared to invasive coronary angigoraphy

    Time frame: Up to 12 weeks

Other outcomes

  1. Possibility of CT-derived FFR in ECG-less CCTA

    We will explore the feasibility of performing fractional flow reserve (FFR)-CT analysis on ECG-less CCTA images. The added diagnostic value of FFR-CT will be evaluated comparing diagnostic accuracy of CCTA with and without FFR, using ICA as the reference.

    Time frame: Up to 12 weeks

  2. Other conditions rather than CAD

    The diagnosis of conditions other than CAD such as aortic dissection, pulmonary embolism, pneumonia, pleural fluid, pneumothorax, and pericardial fluid will be recorded

    Time frame: Up to 12 weeks

  3. Outcome prediction of ECG-less CCTA compared to ICA

    A follow-up at 18 months will assess the occurrence of adverse events (ischemia-driven revascularization, myocardial infarction, and cardiac death). The groups of patients with positive and negative CT scan and ICA will be compared using Chi-squared test or Fisher's exact test as appropriate. For the analysis of binary outcomes, logistic regression will be utilized to establish the binary classifier for ROC curve analysis. Kaplan-Meier curves will be used to describe the event-free survival; differences between groups will be tested with the Log-Rank test. Renal function will be monitored by assessing eGFR at the time of hospitalization, before discharge, and at 18 months.

    Time frame: at 18 months follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kofoed KF, Engstrom T, Sigvardsen PE, Linde JJ, Torp-Pedersen C, de Knegt M, Hansen PR, Fritz-Hansen T, Bech J, Heitmann M, Nielsen OW, Hofsten D, Kuhl JT, Raymond IE, Kristiansen OP, Svendsen IH, Dominguez Vall-Lamora MH, Kragelund C, Hove JD, Jorgensen T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbaek S, Elming H, Therkelsen SK, Jorgensen E, Klovgaard L, Bang LE, Helqvist S, Galatius S, Pedersen F, Abildgaard U, Clemmensen P, Saunamaki K, Holmvang L, Gislason G, Kelbaek H, Kober LV. Prognostic Value of Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2021 Mar 2;77(8):1044-1052. doi: 10.1016/j.jacc.2020.12.037. PubMed 33632478 ↗
  • Linde JJ, Hove JD, Sorgaard M, Kelbaek H, Jensen GB, Kuhl JT, Hindso L, Kober L, Nielsen WB, Kofoed KF. Long-Term Clinical Impact of Coronary CT Angiography in Patients With Recent Acute-Onset Chest Pain: The Randomized Controlled CATCH Trial. JACC Cardiovasc Imaging. 2015 Dec;8(12):1404-1413. doi: 10.1016/j.jcmg.2015.07.015. Epub 2015 Nov 11. PubMed 26577263 ↗
  • Litt HI, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, Leaming JM, Gavin LJ, Pacella CB, Hollander JE. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012 Apr 12;366(15):1393-403. doi: 10.1056/NEJMoa1201163. Epub 2012 Mar 26. PubMed 22449295 ↗
  • Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, Pope JH, Hauser TH, White CS, Weiner SG, Kalanjian S, Mullins ME, Mikati I, Peacock WF, Zakroysky P, Hayden D, Goehler A, Lee H, Gazelle GS, Wiviott SD, Fleg JL, Udelson JE; ROMICAT-II Investigators. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012 Jul 26;367(4):299-308. doi: 10.1056/NEJMoa1201161. PubMed 22830462 ↗
  • Wang K, Zhang Y, Chen B, Ren H. Comparing image quality of coronary CT angiography with and without ECG-gating in wide-detector CT. Front Cardiovasc Med. 2025 Apr 11;12:1570743. doi: 10.3389/fcvm.2025.1570743. eCollection 2025. PubMed 40290191 ↗
  • Linde JJ, Kelbaek H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, Heitmann M, Nielsen OW, Hofsten D, Kuhl JT, Raymond IE, Kristiansen OP, Svendsen IH, Vall-Lamora MHD, Kragelund C, de Knegt M, Hove JD, Jorgensen T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbaek S, Elming H, Therkelsen SK, Jorgensen E, Klovgaard L, Bang LE, Hansen PR, Helqvist S, Galatius S, Pedersen F, Abildgaard U, Clemmensen P, Saunamaki K, Holmvang L, Engstrom T, Gislason G, Kober LV, Kofoed KF. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Feb 11;75(5):453-463. doi: 10.1016/j.jacc.2019.12.012. PubMed 32029126 ↗
  • Meier D, Andreini D, Cosyns B, Skalidis I, Storozhenko T, Mahendiran T, Assanelli E, Sonck J, Roosens B, Rotzinger DC, Qanadli SD, Tzimas G, Muller O, De Bruyne B, Collet C, Fournier S. Usefulness of FFR-CT to exclude haemodynamically significant lesions in high-risk NSTE-ACS. EuroIntervention. 2025 Jan 6;21(1):73-81. doi: 10.4244/EIJ-D-24-00779. PubMed 39468963 ↗
  • Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Curzen N, Keating L, Kardos A, Felmeden D, Lee RJ, Thokala P, Lewis SC, Newby DE; RAPID-CTCA Investigators. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ. 2021 Sep 29;374:n2106. doi: 10.1136/bmj.n2106. PubMed 34588162 ↗
  • Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Juni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191. No abstract available. PubMed 37622654 ↗
  • Thomsen B, Nabipoor A, Asadian S, Reiser I, Cotella J, Okerlund D, Challman M, Landeras L, Chalian H. Coronary computed tomography angiography without ECG leads; A feasibility study. Curr Probl Diagn Radiol. 2026 May-Jun;55(3):426-431. doi: 10.1067/j.cpradiol.2025.04.019. Epub 2025 Apr 29. PubMed 40328582 ↗
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available. PubMed 39210710 ↗
  • SCOT-HEART Investigators; Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah ASV, Timmis AD, van Beek EJR, Williams MC. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018 Sep 6;379(10):924-933. doi: 10.1056/NEJMoa1805971. Epub 2018 Aug 25. PubMed 30145934 ↗
  • Mancini GBJ, Leipsic J, Budoff MJ, Hague CJ, Min JK, Stevens SR, Reynolds HR, O'Brien SM, Shaw LJ, Manjunath CN, Mavromatis K, Demkow M, Lopez-Sendon JL, Chernavskiy AM, Gosselin G, Schuchlenz H, Devlin GP, Chauhan A, Bangalore S, Hochman JS, Maron DJ. CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. JACC Cardiovasc Imaging. 2021 Jul;14(7):1384-1393. doi: 10.1016/j.jcmg.2020.11.012. Epub 2021 Jan 13. PubMed 33454249 ↗
  • Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Bertella E, Antonioli L, Formenti A, Cortinovis S, Veglia F, Annoni A, Agostoni P, Montorsi P, Ballerini G, Fiorentini C, Pepi M. A long-term prognostic value of coronary CT angiography in suspected coronary artery disease. JACC Cardiovasc Imaging. 2012 Jul;5(7):690-701. doi: 10.1016/j.jcmg.2012.03.009. PubMed 22789937 ↗
  • Giangiacomi F, Popelier B, Lochy S, Nieboer K, Von Kemp M, Belsack D, Tanaka K, Cosyns B, Argacha JF, De Mey J. OPENing a new ECLECTIC approach to NSTEMI and cardiac arrest using ECG-less coronary computed tomography angiography. Study design and rationale of two prospective clinical studies. Cardiovasc Revasc Med. 2026 Jan;82:36-41. doi: 10.1016/j.carrev.2025.11.009. Epub 2025 Nov 21. PubMed 41314866 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 85 non-industry interventional studies with no phase under Chest Pain, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Sep 25, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192965
Responsible party
Francesco Giangiacomi (Medical Doctor, fellow in interventional cardiology, Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Sep 25, 2025
Start date
Sep 10, 2025
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 25, 2025

Study contacts

Francesco Giangiacomi, Medical Doctor
Contact
francesco.giangiacomi@uzbrussel.be
0039 3347165451
Jean François Argacha, Professor
Contact
Jean-francois.Argacha@uzbrussel.be

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion